Search Results
Your search for this matches 25283 pages
Showing 5551 - 5600Changing the Natural History of ER-Positive, HER2-Negative Breast Cancer With the Introduction of CDK4/6 Inhibition
It has been 14 years since a collaboration between the University of California, Los Angeles (UCLA) and Pfizer identified a unique role for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in estrogen receptor (ER)-positive human cell line models and demonstrated that these agents act...
Hematology Highlights From ASCO 2022
A multitude of presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage in The ASCO Post of the major news stories at the meeting, here we offer summaries of additional studies of special interest...
ASCO 2022: Conversations in Gynecologic Oncology
In this episode, we’re featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube ...
Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL
Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardless of patients’ fitness, according to late-breaking data presented during the European Hematology...
Adherence to VTE Prophylaxis Guidelines After Pancreatic Cancer Surgery
In a U.S. retrospective cohort study reported in JAMA Surgery, Perry et al found that a very small percentage of patients filled prescriptions for guideline-recommended venous thromboembolism (VTE) prophylaxis after undergoing surgery for pancreatic cancer. As stated by the investigators, “VTE is...
Researchers Discover Protein That May Be Associated With Better Prognosis for Patients With Ovarian Cancer
Researchers have discovered that a protein associated with metabolism—and formerly recognized as a potential therapeutic target for ovarian cancer—may instead be associated with a better prognosis for patients with the malignancy. In a report published by Clemente et al in Cancer Research...
Survey Finds More Than 80% of Patients With Cancer and Survivors Say Copay Assistance Programs Help Them Afford Their Prescription Drugs
A new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN) showed that a majority of respondents (83%) who had applied to a copay assistance program and were accepted said the assistance enables them to get the medication they otherwise couldn’t afford. However,...
ASCO Endorses President Biden’s Pick of ASCO Past President Monica M. Bertagnolli, MD, FACS, FASCO, as Incoming Head of National Cancer Institute
Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer of ASCO, issued the following statement on July 21: ASCO applauds President Biden for his reported decision to appoint ASCO Past President Monica M. Bertagnolli, MD, FACS, FASCO, as the new Director of the National Cancer Institute...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
Does Disclosing Maternal Status Affect Children’s Health Behaviors?
Telling children about their mother’s risk of hereditary breast and/or ovarian cancer does not adversely influence the offspring’s lifestyle or quality of life in the long term, according to a new study published by McDonnell et al in the journal Pediatrics. The study looked at the mutation status...
Judging Melanoma Thickness: Comparison of Dermatologists and Machine-Learning Algorithm
Assessing the thickness of melanoma is difficult—whether done by an experienced dermatologist or a well-trained machine-learning algorithm. A study published by Polesie et al in the Journal of the European Academy of Dermatology and Venereology showed that an algorithm and a group of approximately...
Noncytotoxic Maintenance With Niraparib Plus Either Nivolumab or Ipilimumab in Platinum-Sensitive Advanced Pancreatic Cancer
In a single-institution phase Ib/II trial reported in The Lancet Oncology, Kim A. Reiss, MD, and colleagues found that maintenance treatment with niraparib/ipilimumab produced better 6-month progression-free survival rates than niraparib/nivolumab in patients with advanced pancreatic cancer without ...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Two Early-Career Cancer Researchers From Africa Aim to Make a Difference and Never Give Up
In countries with a high income, research in oncology is sponsored by funding agencies and industry, which has meaningfully improved survival outcomes of patients with cancer. In contrast, the African continent is disadvantaged in all aspects of human development, particularly in the fields of...
Use of Menopausal Hormone Therapy and Breast Cancer Mortality
Although aromatase inhibitors are effective in reducing estrogen levels and the risk of cancer recurrence in women diagnosed with hormone receptor–positive breast cancer, they can also cause myriad side effects, including genitourinary problems associated with menopause such as vaginal dryness,...
Living With Hereditary Cancer, Oncologist Mark A. Lewis, MD, Shares His Experiences on Social Media to Assist Others
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, FACP, spoke with Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain Healthcare, Murray, Utah, and Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a social media...
Eprenetapopt/Azacitidine Maintenance After Allogeneic HSCT for TP53-Mutant AML and MDS
In a phase II trial reported in the Journal of Clinical Oncology, Mishra et al found that maintenance treatment with the first-in-class small-molecule p53 reactivator eprenetapopt plus azacitidine following allogeneic hematopoietic stem cell transplantation (HSCT) was associated with “encouraging”...
CancerCare’s Caregiver Decision-Making Survey Results Reveal Gaps in Support for Caregivers, Give Rise to Recommendations for Improving Caregiver Support
CancerCare has released a report entitled “Cancer Caregivers: National Research Report on Shared Treatment Decision-Making.” It details the findings of its caregiver decision-making survey, which polled a nationally representative sample of 2,703 cancer caregivers between February and July 2021....
Caregivers for Patients With Multiple Myeloma Face Mental Health Challenges
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published by O’Donnell in Blood Advances. Although medical professionals have long acknowledged the toll a serious or terminal diagnosis can have...
HER2-Positive Residual Disease
This is Part 4 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of HER2-positive residual disease. The patient ...
HER2-Positive Early-Stage Breast Cancer
This is Part 3 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of HER2-positive early-stage breast cancer....
Metastatic HER2-Positive Breast Cancer With Brain Metastases
This is Part 2 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of metastatic HER2-positive breast cancer with ...
Metastatic HER2-Positive Breast Cancer
This is Part 1 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of metastatic HER2-positive breast cancer. The ...
Affirming Health Equity: A Model for Integrative Health Care
Guest Editor’s Note: Despite the increasing use of complementary modalities that include mind-body therapies and natural products, significant disparities exist in integrative health care. Contributing factors include access to care and affordability. In this installment of The ASCO Post’s...
For Medicaid-Insured Patients With Cancer, Health Insurance Does Not Always Mean Health-Care Access
Although there has been a significant increase in the number of U.S. residents insured through Medicaid since the Patient Protection and Affordable Care Act was signed into law in March 2010, the ability of Medicaid-insured patients to access cancer care services has not been well understood. In a...
Study Examines Quality-of-Life Outcomes Among Patients Participating in Phase III Randomized Trials of Cancer Drugs
In an analysis that evaluated the outcomes of anticancer drug studies in the advanced disease setting with regard to patient quality of life (QOL), improved QOL outcomes were associated with improved overall survival but not with improved progression-free survival. Almost half of the studies that...
Research Examines Which Demographic Is Most Likely to Use Medical Aid in Dying
Researchers analyzed data from each of the 5,329 patients across the United States who used medical aid in dying in the 23 years after Oregon became the first state to legalize the practice (in 1997) and found one demographic dominates the group: well-educated, White patients with cancer. These...
Deciphering the Elusive Origin and Pathways of Brain Metastases
The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from clinical trials of systemic therapies. However, the emergence of molecular targeted therapies has allowed a new treatment approach in patients ...
Tumor Grade and Response to Immune Checkpoint Inhibition in Recurrent or Metastatic Mucosal HNSCC
In a single-institution retrospective cohort study reported in JAMA Otolaryngology–Head & Neck Surgery, Alkhatib et al found a higher rate of response to immune checkpoint inhibitor treatment among patients with histologic high-grade vs low-grade recurrent or metastatic mucosal head and neck...
Study Explores Community Health Worker–Led Intervention’s Impact on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes
In a single-institution study reported in JAMA Oncology, Manali I. Patel, MD, MPH, MS, and colleagues found that the addition of a community health worker–led intervention to usual care resulted in reduced use of acute care, increased advance care planning documentation, increased use of palliative ...
ASCO 2022: Conversations in Genitourinary Oncology
In this episode, we’re featuring two conversations from leaders in the field of genitourinary oncology. These discussions go over long-term findings in prostate cancer and urothelial carcinoma and were both presented at the 2022 ASCO Annual Meeting.
New Antibody Therapy Shows Activity in Patients With Medulloblastoma
Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial has generated promising results for a new blocking antibody therapy that targets ...
Immune-Related Toxic Effects and Treatment Outcomes in Patients With Cancer and Autoimmune Diseases Receiving Immune Checkpoint Inhibitor Therapy
In a single-institution retrospective cohort study reported in JAMA Oncology, Han et al found that patients with autoimmune diseases had similar outcomes with immune checkpoint inhibitor (ICI) therapy for solid tumors as those without autoimmune diseases, with occurrence vs no occurrence of...
Addition of Atezolizumab to Neoadjuvant Pertuzumab/Trastuzumab and Docetaxel in HER2-Positive Early Breast Cancer
In the Korean phase II Neo-PATH trial reported in JAMA Oncology, Ahn et al found that neoadjuvant treatment with atezolizumab, pertuzumab/trastuzumab, and docetaxel produced a pathologic complete response in 61% of patients with HER2-positive stage II/III breast cancer treated with the regimen....
FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors. Two Trials The safety and...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
On July 13, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, adjuvanted, for the prevention of COVID-19 caused by SARS–CoV-2 in individuals aged 18 years and older. “Authorizing an additional COVID-19 vaccine expands the...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Do Bone Marrow Biopsies Aid in Response Assessment for Patients With Follicular Lymphoma?
In a pooled analysis of patients with follicular lymphoma treated in National Clinical Trials Network trials reported in the Journal of Clinical Oncology, Rutherford et al found evidence that bone marrow biopsies can be avoided in response assessment. The investigators stated, “Bone marrow biopsies ...
Expert Point of View: Madhav V. Dhodapkar, MBBS
“BCMA-targeting bispecific antibodies work, showing impressive single-agent activity in heavily pretreated multiple myeloma. This class of agents is likely to become an important component of future antimyeloma therapies, but we must learn how to optimally use them,” said Madhav V. Dhodapkar,...
Responses to Teclistamab Reported in Early-Phase Trial of Highly Refractory Multiple Myeloma
In patients with multiple myeloma exposed or refractory to three standard therapies, treatment with the bispecific antibody teclistamab produced strong and durable responses in the phase I/II MajesTEC-1 study.1 The results of weekly subcutaneous dosing of teclistamab in 165 patients were presented...
Geriatrics Experts Explore Relationship Between Heart Disease and Cancer
Experts’ discussions and recommendations addressing the interface between cancer and heart disease were published by Supriya Mohile, MD, MS, and colleagues in the Journal of the American Geriatrics Society, summarizing sessions from a virtual bench-to-bedside conference hosted by the American...
Poziotinib Shows Activity in EGFR Exon 20–Mutant NSCLC, With Efficacy Dependent on Insertion Location
A phase II clinical trial of poziotinib for patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 mutations found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may ...
New Gene-Profiling Technology Reveals Potential Melanoma Biomarkers
Diagnosing melanoma clinically and under the microscope can be complicated by the presence of melanocytic nevi, otherwise known as birthmarks or moles that are noncancerous. The development of melanoma is a multistep process, where melanocytes mutate and proliferate. Properly identifying melanoma...
Initial Risk Factors and ‘Time to Cure’ in Childhood and Young Adult Acute Lymphoblastic Leukemia
In an analysis of long-term follow-up of the UKALL2003 trial reported in the Journal of Clinical Oncology, Anthony V. Moorman, PhD, and colleagues found that whereas initial risk of relapse in children and young adults with acute lymphoblastic leukemia differed according to risk factors, risk...
CLN-081 Shows Selective Activity in NSCLC With EGFR Exon 20 Insertions
CLN-081, a novel agent targeted to non–small cell lung cancer (NSCLC) cells harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations—ie, the addition of nucleotide base pairs in exon 20 of the EGFR gene, a known oncogenic driver event—holds promise, according to the results of...
EAU22: Trial Shows New Imaging Technology May Be Less Accurate Than MRI in Detecting Prostate Cancer
A team of researchers in Australia and New Zealand reported that magnetic resonance imaging (MRI) scans may be able to detect prostate cancer more accurately than the newer, prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scanning technique. The...
EAU22: ctDNA May Help to Predict Response to Atezolizumab in Patients With Bladder Cancer
Researchers who treated a group of patients with bladder cancer with the immunotherapy atezolizumab after they had undergone surgery have found that patients whose blood contained circulating tumor DNA (ctDNA) responded very well to the treatment. The study was presented at the European Association ...
Risk of Oropharyngeal Cancer After a Positive HPV16-E6 Serology Test
In an analysis from the Human Papillomavirus Cancer Cohort Consortium (HPVC3) reported in the Journal of Clinical Oncology, Robbins et al found substantial risks of oropharyngeal cancer over time among persons, particularly males, with positive results on human papillomavirus (HPV) 16-E6 serologic...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
